BofA raises Amylyx Pharmaceuticals stock price target on model updates By Investing.com

BofA Securities raised its price target on Amylyx Pharmaceuticals to $22 from $19 while keeping a Buy rating, citing upside from avexitide and a $1.8 billion peak sales forecast. The firm also tweaked assumptions, including a lower discount rate at 10% and a less negative terminal growth rate of -10%, while flagging a $4 million milestone payment to Gubra and slightly higher 2026 R&D spending. Amylyx also reported Q4 2025 EPS of -$0.30 versus -$0.34 expected, an 11.76% beat.

Analysis

AMLX is transitioning from a balance-sheet survival story to a catalyst-driven optionality trade, but the market may be underestimating how much of the near-term upside is already tied to one binary readout. The rerating in estimates across multiple sell-side shops suggests the stock is no longer being valued like a distressed biotech; instead, it is starting to trade like a platform with a lead asset that can justify a materially higher probability of commercialization if the next data point is clean.

The second-order effect is that every incremental de-risking event tightens financing risk and raises the value of the rest of the pipeline. That matters because a successful avexitide readout would likely compress the discount rate further and could unlock cheaper capital for follow-on development, while a miss would likely re-anchor the equity back to cash-burn optics and force the market to reprice the entire pipeline as a collection of long-dated shots on goal.

The contrarian read is that consensus may be extrapolating peak-sales rhetoric too aggressively relative to execution risk in a niche indication. A $1.8B peak case is only useful if the company can show reproducible efficacy, clean safety, and a development path that does not require repeated capital raises; in small-cap biotech, dilution and trial pacing often matter more than headline targets. The stock’s recent strength also raises the odds that implied expectations for the next catalyst are already high, leaving asymmetric downside if the data are merely good rather than clearly best-in-class.

Near term, the setup is less about months of gradual fundamentals and more about a few trading sessions around catalyst timing. If the next clinical update is positive, the move can extend quickly because short interest and underownership usually amplify re-rating velocity in names shifting from ‘funding risk’ to ‘execution risk.’ If the update disappoints, the downside can be outsized because the market will likely cut both the growth multiple and the probability of pipeline expansion at the same time.

Key Decisions for Investors

• Maintain a tactical long AMLX into the next clinical catalyst only if sizing is small enough to absorb a 25-35% gap-down; treat it as event optionality, not a core holding.
• For investors already long, consider financing exposure with covered calls 20-30% above spot into the catalyst window to monetize elevated implied volatility while preserving most upside.
• Pair trade: long AMLX vs. short a basket of pre-revenue biotech names with weaker balance sheets; if AMLX de-risks, the market should favor names with cleaner funding and nearer catalysts over cash-burning peers.
• If you want directional exposure, use call spreads rather than outright equity ahead of the readout; asymmetric payoff is attractive because the market can re-rate quickly on confirmation, but downside is limited to premium paid.
• Take profits on 30-50% of a long position into strength before the catalyst if the stock continues to gap higher, because expectation inflation is now the main risk to a clean post-event trade.